Product Description
a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19649991/)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlobeImmune
Company Location: LOUISVILLE CO 80027
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatitis C, Chronic|Hepatitis A
Phase 1: Hepatitis A|Hepatitis C, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| GI-5005-01 | P1 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2007-06-01 |
2019-03-21 |
Treatments |
|
| GI-5005-02 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2012-11-01 |
2019-03-18 |
||
| 2007-005385-12 | P2 |
Completed |
Hepatitis C, Chronic |
2011-04-11 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|